Hims & Hers CEO says FTC lawsuit misunderstands how the company works

Hims & Hers CEO Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit targeting its data sharing and subscription practices. In an interview with CNBC’s “Squawk Box” aired Tuesday, Dudum said the FTC’s claims reflect a misunderstanding of how the company is redesigning healthcare in a digital setting. He also argued that when Hims & Hers sold compounded GLP-1 drugs, it helped lower treatment prices. The FTC, along with Los Angeles County and Utah, filed the lawsuit in July accusing the company of sharing user health information with advertisers such as Meta and Snap, charging for prescriptions before a provider conversation, and making cancellations difficult.